No Early Effect of Intrathecal Rituximab in Progressive Multiple Sclerosis (EFFRITE Clinical Trial)

Table 1

Patient characteristics. Patients 9 and 10 were, respectively, patients 7 and 8 rerandomized to active groups after completion of study in control arm. CP: cyclophosphamide; Ctl: control group; DMF: dimethylfumarate; IFN: interferons; IT: intrathecal rituximab group; IT+IV: intrathecal and intravenous rituximab group; MTX: methotrexate; PP: primary progressive MS; SP: secondary progressive MS.

#	Group	Gender/age	MS type	Disease duration (years)	Baseline EDSS	Previous therapies
7	Ctl	F/49	SP	16	6.5	CP, DMF
8	Ctl	F/67	SP	40	6	None
1	IT	M/64	PP	15	6	MTX
4	IT	M/50	SP	25	7	IFN, CP
5	IT	F/65	SP	35	8	MTX
6	IT	M/60	SP	6	6	MTX, CP
2	IT+IV	F/62	PP	16	8	MTX, IFN
3	IT+IV	M/61	SP	22	7.5	Steroids
9	IT+IV	F/52	SP	18	6.5	CP, DMF
10	IT+IV	F/68	SP	42	6	None